Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, January 31st. The business's quarterly revenue was up 7.2% compared to the same quarter past year. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.98 by $0.03. The share price was last updated to $84.14 with a loss of -0.22 points or -0.26%.
The stock has a high price target of $80 according to consensus of 23 analysts.
Eli Lilly and Company (NYSE:LLY) remains a strong buy in the latest set of rankings. Analyst's mean target price for AUPH is $10.30 while analysts mean recommendation is 1.40. Goldman Sachs Group Inc upgraded Eli Lilly and from a "buy" rating to a "conviction-buy" rating in a research report on Thursday, December 15th.
Some buy side analysts are also providing their Analysis on Eli Lilly and Company, where 6 analysts have rated the stock as Strong buy, 11 analysts have given a Buy signal, 5 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. The mean PT for this stock is at $86.55 while the max. level suggested by the brokerage firms is $103.00 and min. PT is $70.00.
Eli Lilly and Company (NYSE:LLY) plunged -1.04% with the closing price of $84.99. State Street Corp now owns 41,712,511 shares of the company's stock worth $3,067,953,000 after buying an additional 1,945,594 shares during the last quarter. The company has a market capitalization of $90.25 billion, a price-to-earnings ratio of 33.29 and a beta of 0.30. The recent trading ended with the price almost 0.37 higher for the last 5 trading days, rebounding 31.98% from its 52-week low. The firm's 50 day moving average price is $80.34 and its 200 day moving average price is $76.98.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Tudor Investment Corp Et Al boosted its position in shares of Eli Lilly and by 124.2% in the fourth quarter. The stock appeared 1.31% below its 52-week highs and is up 2.96% for the last five trades. Bank of New York Mellon Corp boosted its stake in shares of Eli Lilly and by 6.9% in the third quarter. Its share price has risen 14.13% in three months and is up 7.25% for the last five trades. Financial Architects Inc boosted its stake in Eli Lilly and by 4.5% in the third quarter. The company has a market cap of $92,836 million and there are 1,103,352,450 shares in outstanding.
In related news, major shareholder Lilly Endowment Inc sold 230,000 shares of Eli Lilly and stock in a transaction on Friday, February 17th. Finally, Penserra Capital Management LLC increased its stake in Eli Lilly and by 100.0% in the third quarter. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 66,415,305 shares of the stock are valued at $5.6 billion.
In other Eli Lilly and news, Director R David Hoover bought 500 shares of the stock in a transaction that occurred on Friday, December 16th. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. Following the completion of the sale, the senior vice president now directly owns 45,583 shares of the company's stock, valued at approximately $3,539,975.78.
In the transaction dated February 02, 2017, the great number of shares disposed came courtesy the Chief Accounting Officer; Zakrowski Donald A disposed a total of 2,000 shares at an average price of $77.52, amounting to approximately $155,040. The disclosure for this purchase can be found here. The volume of the company in the last trading session was 4.7 Million.
Institutional investors now hold around $70.48 billion or 76.7% in LLY stock.
Eli Lilly and Company is engaged in drug manufacturing business.